Seegene and Molzym partner on automated molecular sepsis diagnostics
Seegene and Molzym announced a partnership on the automated Magicplex™ sepsis, a new multi-pathogen screening test capable of quick and accurate identification of over 90 leading sepsis-causing pathogens.
"The Magicplex Sepsis Test will be the new gold standard for performing accurate, rapid and cost-effective sepsis diagnosis," said Dr. Jong-Yoon Chun, chief executive officer of Seegene. "In treating sepsis, time and accuracy are demanded. Every hour of delay in giving patients the correct antibiotics results in an 8% increase in the mortality rate."
“The automation reduces the total process costs significantly and makes Magicplex Sepsis Test the first true routine sepsis test worldwide” says Prof. Dr. Michael Lorenz, Chief Scientific Officer at Molzym.
Other news from the department business & finance
